Specializing In:Evaluation of tobacco policies, Cancer and tobacco surveillance, Biostatistical support
About Andrew Hyland
Dr. Andrew Hyland has more than 25 years of experience doing tobacco control research. He has conducted numerous funded clinical and population-based studies, published more than 300 papers, and is widely recognized nationally and internationally for his expertise, including advisory roles for the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention, the National Cancer Institute and the International Agency for Research on Cancer. From 2006-2016, he served as the Deputy Editor for the scientific journal Tobacco Control, the leading international journal for tobacco control scientists.
As the Chair of the Department of Health Behavior at Roswell Park Comprehensive Cancer Center, he directs the New York State Smokers Quitline and has contracts with the New York State Department of Health to work with community and clinical stakeholders to advance their tobacco control work plan. He serves as the Scientific Leader of the Population Assessment of Tobacco and Health (PATH) study, which is supported by the National Institute on Drug Abuse (NIDA) and the Food and Drug Administration (FDA) to study more than 46,000 adults and children nationally over a 14-year period to understand changes in tobacco use behaviors and health. Dr. Hyland is a co-investigator for the International Tobacco Control Study, tracking cohorts of tobacco users in 29 countries to evaluate tobacco control policies.
- Professor of Oncology
- Chair, Department of Health Behavior, Division of Cancer Prevention and Population Sciences
- The Robert, Ann and Lew Wallace Endowed Chair in Health Behavior
Education and Training:
- PhD - Epidemiology and Community Health, State University of New York at Buffalo, Buffalo, New York
- MA - Statistics, State University of New York at Buffalo, Buffalo, New York
- BA - Mathematics, State University of New York at Buffalo, Buffalo, New York
Dr. Hyland’s research focuses on primary prevention and providing an evidence base to inform population-based tobacco regulations that serve to reduce the disease burden caused by tobacco. He oversees both service and research efforts that are focused on moving populations to reduce their cancer risk, particularly through evidence-based policy implementation such as smoke-free air policies and tobacco product regulation. Dr. Hyland also takes on other important policy-relevant topics in tobacco control research, including identifying strategies to boost the reach and efficacy of stop smoking intervention, assessing the effectiveness of mass media anti-smoking campaigns, evaluating the impact of changes in product design and packaging, and surveillance of tobacco use, the tobacco industry and other tobacco-related issues.
Featured on Cancer Talk
Showing all3 of 5 CollapseView all
Stanton CA, Sharma E, Edwards KC, Halenar MJ, Taylor KA, Kasza KA, Day H, Anic G, Gardner LD, Hammad HT, Bansal-Travers M, Limpert J, Borek N, Kimmel HL, Compton WM, Hyland A. Longitudinal transitions of exclusive and polytobacco electronic nicotine delivery systems (ENDS) use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1-3 (2013-2016). Tob Control. 2020 May;29(Suppl 3):s147-s154. doi: 10.1136/tobaccocontrol-2019-055574. PubMed PMID:32321848; PubMed Central PMCID:PMC7530834.
Goniewicz ML, Smith DM, Edwards KC, Blount BC, Caldwell KL, Feng J, Wang L, Christensen C, Ambrose B, Borek N, van Bemmel D, Konkel K, Erives G, Stanton CA, Lambert E, Kimmel HL, Hatsukami D, Hecht SS, Niaura RS, Travers M, Lawrence C, Hyland AJ. Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. JAMA Netw Open. 2018 Dec 7;1(8):e185937.
Kasza KA, Ambrose BK, Conway KP, Borek N, Taylor K, Goniewicz ML, Cummings KM, Sharma E, Pearson JL, Green VR, Kaufman AR, Bansal-Travers M, Travers MJ, Kwan J, Tworek C, Cheng YC, Yang L, Pharris-Ciurej N, van Bemmel DM, Backinger CL, Compton WM, Hyland AJ. Tobacco-Product Use by Adults and Youths in the United States in 2013 and 2014. N Engl J Med. 2017 Jan 26;376(4):342-353. doi: 10.1056/NEJMsa1607538. PubMed PMID:28121512; PubMed Central PMCID:PMC5317035
Hyland A, Ambrose BK, Conway KP, Borek N, Lambert E, Carusi C, Taylor K, Crosse S, Fong GT, Cummings KM, Abrams D, Pierce JP, Sargent J, Messer K, Bansal-Travers M, Niaura R, Vallone D, Hammond D, Hilmi N, Kwan J, Piesse A, Kalton G, Lohr S, Pharris-Ciurej N, Castleman V, Green VR, Tessman G, Kaufman A, Lawrence C, van Bemmel DM, Kimmel HL, Blount B, Yang L, O'Brien B, Tworek C, Alberding D, Hull LC, Cheng YC, Maklan D, Backinger CL, Compton WM. Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tob Control. 2017 Jul;26(4):371-378. doi: 10.1136/tobaccocontrol-2016-052934. Epub 2016 Aug 8. PubMed PMID:27507901; PubMed Central PMCID:PMC5299069.
Ambrose BK, Day HR, Rostron B, Conway KP, Borek N, Hyland A, Villanti AC. Flavored Tobacco Product Use Among US Youth Aged 12-17 Years, 2013-2014. JAMA. 2015 Nov 3;314(17):1871-3.